808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy

• Patrick Hwu,
• Apoorvi Chaudhri,
• Ping Hua,
• Xia Bu,
• Michael A Davies,
• Yunfei Wang,
• Shao-Hsi Hung,
• Ulrich Von Andrian,
• Gordon Freeman,
• Gregory A Lizee

Affiliations

Patrick Hwu

1Moffitt Cancer Center, Tampa, FL, USA

Apoorvi Chaudhri

1Dana-Farber Cancer Institute, Boston, MA, USA

Ping Hua

1Dana-Farber Cancer Institute, Boston, MA, USA

Xia Bu

3Harvard Medical School, Boston, MA, USA

Michael A Davies

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Yunfei Wang

5H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAs

Shao-Hsi Hung

4The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ulrich Von Andrian

3Harvard Medical School, Boston, MA, USA

Gordon Freeman

1Dana-Farber Cancer Institute, Boston, MA, USA

Gregory A Lizee

4The University of Texas MD Anderson Cancer Center, Houston, TX, USA